Medico Remedies Limited
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics… Read more
Medico Remedies Limited (MEDICO) - Net Assets
Latest net assets as of September 2025: ₹668.58 Million INR
Based on the latest financial reports, Medico Remedies Limited (MEDICO) has net assets worth ₹668.58 Million INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.37 Billion) and total liabilities (₹704.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹668.58 Million |
| % of Total Assets | 48.67% |
| Annual Growth Rate | 23.31% |
| 5-Year Change | 92.46% |
| 10-Year Change | 323.7% |
| Growth Volatility | 22.84 |
Medico Remedies Limited - Net Assets Trend (2013–2025)
This chart illustrates how Medico Remedies Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medico Remedies Limited (2013–2025)
The table below shows the annual net assets of Medico Remedies Limited from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹624.69 Million | +19.28% |
| 2024-03-31 | ₹523.71 Million | +19.45% |
| 2023-03-31 | ₹438.43 Million | +17.48% |
| 2022-03-31 | ₹373.20 Million | +14.98% |
| 2021-03-31 | ₹324.58 Million | +8.68% |
| 2020-03-31 | ₹298.66 Million | +5.77% |
| 2019-03-31 | ₹282.36 Million | +5.89% |
| 2018-03-31 | ₹266.66 Million | +62.88% |
| 2017-03-31 | ₹163.72 Million | +11.04% |
| 2016-03-31 | ₹147.44 Million | +8.30% |
| 2015-03-31 | ₹136.14 Million | +58.82% |
| 2014-03-31 | ₹85.72 Million | +69.56% |
| 2013-03-31 | ₹50.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medico Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3134.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹423.00 Million | 67.71% |
| Common Stock | ₹165.97 Million | 26.57% |
| Other Comprehensive Income | ₹2.40 Million | 0.38% |
| Other Components | ₹33.32 Million | 5.33% |
| Total Equity | ₹624.69 Million | 100.00% |
Medico Remedies Limited Competitors by Market Cap
The table below lists competitors of Medico Remedies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Visionary Copper and Gold Mines Inc.
F:CAX
|
$8.48 Million |
|
Prajay Engineers Syndicate Limited
NSE:PRAENG
|
$8.49 Million |
|
Sterling Metals Corp
OTCQB:SAGGF
|
$8.49 Million |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
$8.49 Million |
|
Dataprep Holdings Bhd
KLSE:8338
|
$8.48 Million |
|
Aeffe S.p.A.
LSE:0GY8
|
$8.48 Million |
|
IDT Australia Ltd
AU:IDT
|
$8.48 Million |
|
Poulaillon SA
PA:ALPOU
|
$8.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medico Remedies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 523,710,000 to 624,689,000, a change of 100,979,000 (19.3%).
- Net income of 100,932,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 47,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹100.93 Million | +16.16% |
| Other Comprehensive Income | ₹47.00K | +0.01% |
| Total Change | ₹- | 19.28% |
Book Value vs Market Value Analysis
This analysis compares Medico Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 64.04x to 5.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | ₹0.61 | ₹39.01 | x |
| 2014-03-31 | ₹1.03 | ₹39.01 | x |
| 2015-03-31 | ₹1.64 | ₹39.01 | x |
| 2016-03-31 | ₹1.78 | ₹39.01 | x |
| 2017-03-31 | ₹1.97 | ₹39.01 | x |
| 2018-03-31 | ₹3.98 | ₹39.01 | x |
| 2019-03-31 | ₹3.40 | ₹39.01 | x |
| 2020-03-31 | ₹3.60 | ₹39.01 | x |
| 2021-03-31 | ₹3.91 | ₹39.01 | x |
| 2022-03-31 | ₹4.49 | ₹39.01 | x |
| 2023-03-31 | ₹5.28 | ₹39.01 | x |
| 2024-03-31 | ₹6.31 | ₹39.01 | x |
| 2025-03-31 | ₹7.55 | ₹39.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medico Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.16%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.69%
- • Asset Turnover: 1.26x
- • Equity Multiplier: 1.92x
- Recent ROE (16.16%) is above the historical average (9.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 8.46% | 1.27% | 1.84x | 3.63x | ₹-780.30K |
| 2014 | 7.34% | 1.40% | 1.44x | 3.64x | ₹-2.28 Million |
| 2015 | 5.82% | 1.55% | 1.43x | 2.63x | ₹-5.69 Million |
| 2016 | 7.66% | 1.69% | 1.46x | 3.09x | ₹-3.44 Million |
| 2017 | 9.94% | 2.99% | 1.13x | 2.95x | ₹-90.80K |
| 2018 | 4.58% | 2.00% | 1.03x | 2.23x | ₹-14.46 Million |
| 2019 | 5.56% | 1.61% | 1.28x | 2.70x | ₹-12.53 Million |
| 2020 | 5.46% | 1.84% | 1.18x | 2.52x | ₹-13.56 Million |
| 2021 | 7.98% | 2.12% | 1.62x | 2.33x | ₹-6.56 Million |
| 2022 | 12.89% | 3.98% | 1.59x | 2.04x | ₹10.80 Million |
| 2023 | 16.52% | 5.16% | 1.61x | 1.99x | ₹28.57 Million |
| 2024 | 15.83% | 5.72% | 1.51x | 1.84x | ₹30.54 Million |
| 2025 | 16.16% | 6.69% | 1.26x | 1.92x | ₹38.46 Million |
Industry Comparison
This section compares Medico Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medico Remedies Limited (MEDICO) | ₹668.58 Million | 8.46% | 1.05x | $8.48 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |